NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/08/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,724 mln
Float315 mln
Earnings Date11/12/2026
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
0.84
Highly suspicious
1-Year Forecast
8.10
Modest upside
Relative Strength
35
/ 100
Underperforming
Debt / Equity
0.01
Debt-free
Pre-Tax Margin
-14,937%
Severely loss-making
Business Description
AtaiBeckley Inc. is a New York-based company founded in 2018 that works to develop new treatments for mental health conditions, operating across the United States, Germany, and Canada. The company focuses on a broad range of experimental medicines targeting conditions such as depression, anxiety, schizophrenia, and alcohol use disorder, with several drugs currently in clinical trials. Many of its treatments are based on psychedelic or psychedelic-inspired compounds, reflecting a growing scientific interest in this area of medicine.
